Qorvo® Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing.
04/15/2021 | Qorvo Biotechnologies Awarded $24.4 Million National Institutes of Health Contract to Scale Point-of-Care COVID-19 Antigen Testing |
04/15/2021 | Qorvo Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing |
03/24/2021 | Qorvo Accelerates 5G Smartphone Design with RF Fusion20™ |
03/22/2021 | Qorvo Launches First Smart Home Device Controller to Support Simultaneous Wireless Communications |
03/05/2021 | Qorvo Technology Enables Perseverance Rover’s Safe Descent to Mars |